Patents
More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)
Patents for C07D - Heterocyclic compounds (10,420)
03/2004
03/10/2004CN1141295C Indoline derivatives as progesterohe antagonists
03/09/2004US6703516 Process for the preparation of 5-carboxyphthalide
03/09/2004US6703506 Amino acid ester containing azole antifungals
03/09/2004US6703502 Spiroazo bicyclic heterocyclic
03/04/2004WO2004018484A1 Beta-lactamase inhibitor prodrug
03/04/2004US20040044215 Crystallization, filtration; neurokinins receptor antagonist
03/04/2004US20040044018 Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor
03/04/2004US20040044009 Drug abuse; cental nervous system disorders; cognition activators
03/04/2004CA2494953A1 Beta-lactamase inhibitor prodrug
03/03/2004EP1394152A1 2-iminoimidazole derivatives (1)
03/03/2004EP1394150A1 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
03/03/2004EP1392694A1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo[2,3]pyrimidine derivatives as protein kinases inhibitors
03/03/2004EP1392666A1 Biologically active methylene blue derivatives
03/03/2004EP1392307A1 Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
03/03/2004EP1307460B1 METHOD FOR THE PRODUCTION OF IMIDAZO-[1,2-c][2,3]-BENZODIAZEPINES AND INTERMEDIATES IN THE PRODUCTION THEREOF
03/03/2004EP1284974B1 Triazolyl tropane derivatives as ccr5 modulators
03/03/2004CN1140525C 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
03/03/2004CN1140516C Quinoline and quinoxaline compounds which inhibits platelet-derived growth factor on/or p56lck tyrosine kinases
03/03/2004CN1140503C Triazepiones, compound process for their preparation and their therapeutic application
03/02/2004US6699996 Production method of isoxazolidinedione compound
03/02/2004US6699891 Npyy5 antagonists
03/02/2004CA2189007C Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
03/02/2004CA2138289C N-substituted azabicycloheptane derivatives, the preparation and use thereof
02/2004
02/26/2004WO2004016106A1 Method for producing an unsaponifiable matter of avocado rich in furan lipids
02/26/2004US20040039005 HIV replication inhibiting pyrimidines
02/26/2004US20040038977 Treating arthritis, pain and cancer
02/26/2004US20040038957 Anti-malarial activity
02/25/2004EP1391456A1 2-iminoimidazole derivative (2)
02/25/2004EP1391451A1 2-iminopyrrolidine derivates
02/25/2004EP1390366A1 The citrate salt of 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene
02/25/2004EP1390349A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
02/25/2004EP1087934B1 Aminocyclohexyl ether compounds and uses thereof
02/25/2004CN1139595C Crystalline macrolides and its preparation method
02/25/2004CN1139578C Preparation of isoxazoline-3-yl-acyl benzene
02/24/2004US6696567 Pyrrolo[2,3-d]pyrimidine compounds
02/24/2004US6696481 Immediate-release tablets; treatment of arterial hypertension and heart failure
02/19/2004WO2004014851A2 Tyrosine kinase inhibitors
02/19/2004US20040034234 Adding sulfur dioxide to a mixture containing a cyanopyrazole 4-yl disulfide compound, a formate salt, trifluoromethyl bromide and a polar solvent to form 4-trifluoromethylthiopyrazole compound
02/19/2004US20040034230 Taxanes having a carbamoyloxy substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substitutions; anticarcinogenic agent
02/18/2004EP1192156B1 Bispidine compounds useful in the treatment of cardiac arrhythmias
02/18/2004EP1133477B1 Substituted benzimidazoles and their use as parp inhibitors
02/18/2004CN1476434A Novel compounds
02/18/2004CN1476429A EP4 receptor selective agonists in treatment of osteoporosis
02/18/2004CN1138778C Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
02/17/2004US6693117 Compounds with analgesic effect
02/17/2004US6693111 Indole-2,3-dione-3-oxime derivatives
02/17/2004CA2302965C Processes and intermediates for preparing anti-cancer compounds
02/12/2004WO2004012496A2 Method for producing an avocado unsaponifiable rich in furan lipids
02/12/2004WO2003079787A9 Synergistic fungicide compositions containing at least one n-`(2-pyridinyl)methyl!-3-pyridinecarboxamide derivative and one or more further fungicides useful for controlling fungal plant diseases
02/12/2004WO2003010159A8 Piperidine derivatives as nmda receptor antagonists
02/11/2004EP1387844A1 Retinol derivatives potentiation of active substances by micellar preparation
02/11/2004EP1006110B1 Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments
02/11/2004CN1473831A Process for preparing pyrazolo (4,3-d) pyrimidine-7-ketone and its intermediate
02/11/2004CN1137891C Process for preparing growth hormone cinogenic agent
02/10/2004US6689881 Method for preparing substituted [1,4]diazepino[6,7,1-hi]indol-4-ones
02/10/2004US6689797 Tetrahydropyridines, preparation method and pharmaceutical compositions containing same
02/10/2004US6689761 Compound j, nucleoside analog hiv reverse transcriptase inhibitor 3tc and azt
02/10/2004CA2297134C A novel process for preparing intermediates or inhibitors of enkephalinase and angiotensin converting enzyme and intermediates thereof
02/05/2004WO2004011426A2 Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry
02/05/2004WO2004011425A2 Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives
02/05/2004WO2003080580A3 Quinoline derivatives and their use as 5-ht6 ligands
02/05/2004US20040024190 Viral polymerase inhibitors
02/05/2004US20040023973 Novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof.
02/05/2004US20040023955 Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
02/05/2004CA2494715A1 Method for automated, large-scale measurement of the molecular flux rates using mass spectrometry
02/04/2004EP1386921A1 Intermediates
02/04/2004EP1386917A1 Intermediates
02/04/2004EP1386912A1 Cyclic amidine derivative
02/04/2004EP1386909A1 Cyclopropane amines
02/04/2004EP0992503B1 Process for producing isooxazolidinedione compound
02/04/2004EP0983264B1 Method of manufacturing sertindole
02/04/2004CN1137097C Aminoalkyl-3,4-dihydroquindine derivates as No-synthase inhibitors
01/2004
01/29/2004WO2004009550A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
01/29/2004WO2004009541A2 Antisense modulation of endothelial lipase expression
01/29/2004WO2003042172A3 C-5 modified indazolylpyrrolotriazines
01/29/2004US20040019207 Amines such as 8-Benzyl-3-(3-pyridyl)-8-azabicyclo(3.2.1) oct-2-ene, that bind to nicotinic acetocholine receptors, used for prophylaxis of nervous system disorders, as analgesis, antiinflammatory agents and drug abuse
01/29/2004US20040019103 Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof
01/29/2004US20040019100 HMG CoA-reductase inhibitors
01/29/2004US20040019056 Anititumoral analogs of et-743
01/29/2004US20040019041 Method for the production of imidazo-(1,2-C)(2,3)-benzodiazepines and intermediates in the production thereof
01/29/2004US20040018258 Process for obtaining a furan lipid-rich unsaponifiable material from avocado
01/29/2004CA2492651A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
01/28/2004EP1384722A1 Process for the production of 2-(5-methyl-4-oxazolyl)acetates
01/28/2004EP0839028B1 Solid dispersions of rapamycin
01/28/2004CN1471534A 桥(连)哌嗪衍生物 Bridge (even) piperazine derivatives
01/28/2004CN1136191C Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists
01/28/2004CN1135982C Process for preparing pharmaceutical composition containing N-acyl-2,3-benzodiazepine deriratives
01/27/2004US6683105 Highly selective butyrylcholinesterase inhibitors such as cymserine or others can prevent or treat cognitive impairments associated with aging or alzheimer's disease
01/27/2004US6683079 Reverse transcriptase inhibitors
01/22/2004WO2004007451A1 Indole-3-sulphur derivatives
01/22/2004US20040014976 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
01/22/2004US20040014794 Use of hydroxypyridone-derivatives in wound healing
01/22/2004US20040014767 Central nervous system diosrders; antidepressants, anxiolytic agents, anxiolytic agents
01/22/2004CA2492445A1 Indole-3-sulphur derivatives
01/21/2004CN1469878A Aza-and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
01/21/2004CN1469864A Process for preparing cilostazol
01/20/2004US6680329 N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants
01/15/2004WO2004005295A1 Novel tricyclic spiropiperidines or spiropyrrolidines
01/15/2004WO2004005250A1 Hmg-coa reductase inhibitors
01/15/2004US20040010151 Lansoprazole polymorphs and processes for preparation thereof
1 ... 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 ... 105